

ONCOCROSS

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	Oncocross
○ Representative	Yirang Kim
○ Establishment year	2015
○ Specialized Field	Drug Development using AI platform
○ Address	16F, 11, Seacahng-ro, Mapo-gu, Seoul 04168
○ Home page	- Homepage: www.oncocross.com
○ Enterprise Brief Introduction	Oncocross is an AI drug development company that predicts the interaction between drugs and diseases using AI (Artificial Intelligence) based on gene expression patterns. We started based on a platform technology that searches for a disease that is predicted to have this effect or, on the contrary, searches for a drug that is expected to have an effect on the disease.
○ Product and Pipeline Introduction	<p>RAPTOR AI®: As an AI drug development platform that focuses on screening the optimal indications for drugs, it is possible to derive new indications for new clinical drugs or approved drugs already on the market, or to improve efficacy through concurrent administration. It plays a role in reducing the risk of failure in the new drug development stage and shortening the development period by deriving treatment combinations. We have 17 pipelines that treat liver diseases, cancer, rare diseases, cardiovascular disease, infectious diseases, skin diseases, Central nervous system, and metabolic diseases identified by RAPTOR AI.</p> <p>ONCOFind AI®: Predicts the optimal treatment option and timing to increase the survival rate of cancer patients by quickly and accurately predicting the primary site of primary and unknown metastatic cancer, which accounts for 2-6% of all cancer cases.</p>
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	<p>8 papers related to AI platform and its pipeline</p> <p>Total 28 patents including 8 PCT, 20 domestic patents related AI platform and pipeline</p> <p>Investment of Series A (6 billion won) and Series B (16.5 billion won)</p>